[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY33975A - Formulaciones de otamixaban con estabilidad mejorada - Google Patents

Formulaciones de otamixaban con estabilidad mejorada

Info

Publication number
UY33975A
UY33975A UY0001033975A UY33975A UY33975A UY 33975 A UY33975 A UY 33975A UY 0001033975 A UY0001033975 A UY 0001033975A UY 33975 A UY33975 A UY 33975A UY 33975 A UY33975 A UY 33975A
Authority
UY
Uruguay
Prior art keywords
otamixaban
formulations
improved stability
stability
improved
Prior art date
Application number
UY0001033975A
Other languages
English (en)
Inventor
Dr Walter Kamm
Dr Till Bussemer
Dr Doris Andert
Dr Bernd Kuehn
Dr Ernst-Josef Todt
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33975A publication Critical patent/UY33975A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende (2R.3R)-2-{3-[amino(imino)metil]bencil}-3-{[4-(1-oxidopiridin-4-il)benzoil]amino}butanoato de metilo o una sal farmacéuticamente aceptable del mismo y un compuesto reactivo ácido farmacéuticamente aceptable, o a una solución o dispersión acuosa de la composición así como a un procedimiento para la preparación de la misma, a métodos para usar tales composiciones para tratar a su jetos que sufren enfermedades que se pueden mejorar por la administración de un inhibidor del Factor Xa.
UY0001033975A 2011-03-29 2012-03-27 Formulaciones de otamixaban con estabilidad mejorada UY33975A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305347 2011-03-29

Publications (1)

Publication Number Publication Date
UY33975A true UY33975A (es) 2012-10-31

Family

ID=44584895

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033975A UY33975A (es) 2011-03-29 2012-03-27 Formulaciones de otamixaban con estabilidad mejorada

Country Status (18)

Country Link
US (3) US20120252852A1 (es)
EP (1) EP2691075A1 (es)
JP (1) JP5993933B2 (es)
KR (1) KR101844623B1 (es)
CN (1) CN103561723B (es)
AR (1) AR085580A1 (es)
AU (1) AU2012234323A1 (es)
BR (1) BR112013024801A2 (es)
CA (1) CA2830962C (es)
CO (1) CO6801755A2 (es)
EA (1) EA025572B1 (es)
IL (1) IL228573A (es)
MA (1) MA35050B1 (es)
MX (1) MX342324B (es)
SG (1) SG193932A1 (es)
UY (1) UY33975A (es)
WO (1) WO2012130819A1 (es)
ZA (1) ZA201308061B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691075A1 (en) 2011-03-29 2014-02-05 Sanofi Otamixaban formulations with improved stability
PL3239134T3 (pl) 2013-01-31 2021-06-14 Vertex Pharmaceuticals Incorporated Pirydonoamidy jako modulatory kanałów sodowych
DE102013212933B3 (de) * 2013-07-03 2014-11-27 Schaeffler Technologies Gmbh & Co. Kg Lageranordnung in einem Elektromotor
PT3668516T (pt) 2017-08-16 2021-12-23 Merck Patent Gmbh Liofilizados estáveis que compreendem ácido 5,10-metileno-(6r)-tetra-hidrofólico e um ácido dicarboxílico
CN109010273B (zh) * 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030272A (en) * 1960-05-26 1962-04-17 Abbott Lab Stable heaparin solution
WO1994012030A1 (en) 1992-11-27 1994-06-09 Napro Biotherapeutics, Inc. Injectable composition
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
SI0906094T1 (en) 1996-01-02 2003-12-31 Aventis Pharmaceuticals Inc. Substituted n- (aminoiminomethyl or aminomethyl)phenyl)propyl amides
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
PE20121401A1 (es) * 2009-07-29 2012-10-25 Sanofi Sa Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st
RU2597423C2 (ru) 2011-03-29 2016-09-10 Санофи Бензойнокислая соль отамиксабана
EP2691075A1 (en) 2011-03-29 2014-02-05 Sanofi Otamixaban formulations with improved stability

Also Published As

Publication number Publication date
WO2012130819A1 (en) 2012-10-04
EA201391406A1 (ru) 2014-02-28
CA2830962A1 (en) 2012-10-04
CN103561723B (zh) 2016-04-20
EA025572B1 (ru) 2017-01-30
SG193932A1 (en) 2013-11-29
MA35050B1 (fr) 2014-04-03
US20170224668A1 (en) 2017-08-10
JP5993933B2 (ja) 2016-09-14
CA2830962C (en) 2019-06-18
EP2691075A1 (en) 2014-02-05
AU2012234323A1 (en) 2013-10-17
NZ616180A (en) 2015-10-30
US20120252852A1 (en) 2012-10-04
KR20140019818A (ko) 2014-02-17
ZA201308061B (en) 2015-01-28
US20140018398A1 (en) 2014-01-16
KR101844623B1 (ko) 2018-04-02
JP2014509621A (ja) 2014-04-21
CN103561723A (zh) 2014-02-05
IL228573A0 (en) 2013-12-31
MX342324B (es) 2016-09-23
MX2013011260A (es) 2014-03-27
AR085580A1 (es) 2013-10-09
BR112013024801A2 (pt) 2016-12-20
US9993464B2 (en) 2018-06-12
IL228573A (en) 2017-12-31
CO6801755A2 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
UY34374A (es) Benzilindazoles sustituidos
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34515A (es) Triazolopiridinas sustituidas
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34034A (es) Triazolopiridinas
UY34039A (es) Compuestos fungicidas
UY34559A (es) Inhibidores de bromodominios
UY34550A (es) Bencilpirazoles sustituidos
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34648A (es) Amidas como inhibidores de pim
UY33978A (es) Piridinonas bicíclicas nuevas.
UY34006A (es) Imidazopiridazinas
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34765A (es) Compuestos novedosos.
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY34817A (es) Tienopirimidinas
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
UY4149Q (es) Golosina para mascota
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
UY34523A (es) Derivados de betulina
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019